The serologic reactivity and epidemiology associated with different hepatitis C virus (HCV) variants were investigated in a cohort of 113 anti-HCV-posilive donors. In Scotland, HCV type 1 accounted for one-half of all infections; 40 percent of subjects were infected with HCV type 3, and the remainder were Infected with type 2. Reac tivity with the NS-4-encoded antigens in the first-generation anti-c100 assay was absent in 68 percent of donors infected with types 2 and 3, as compared with 10 percent for those Infected with type 1. Even when combined with surrogate marker testing, first-generation tests would have failed to detect 12 percent of HCV-lnfected blood donors. The age distribution, incidence of past infection with hepatitis B virus, and reported risk factors were similar in donors infected with types 1 and 3 (mean ages were 31.9 and 29.9; 18 and 17.5% were positive for antibody to hepatitis B core antigen; and 47 and 48% had past intravenous drug abuse). However, the distributions of alanine aminotransferase levels were significantly different In those infected with type 3 (abnormally raised in 83%) and those Infected with type 1 (55% abnormal alanine aminotransferase; p<0.05) or type 2 (60%; p<0.01) ana those who were nonviremic (8%; p<0.0001). These data suggest that HCV type 1 Is the most common HCV Infection in blood donors and that infection with HCV type 3 may be associated with more severe liver disease, because of more recent Infection or be cause of a greater inherent pathogenicity of type 3 variants. TRANSFUSION 1993;33:7-13.
Another possible cause of false-negative results is the existence of HCV variants that elicit antibodies that fail to react with currently available antigens. Extreme se quence variants of HCV, 6 " 10 variously described as K2 6 or type III, 11 have been reported, that have only 65 per cent overall sequence homology with the prototype virus (HCV-1) 2 and other variants from Japanese patients.
12,13
Recently, we discovered another major type of HCV that was equally distinct from the prototype virus. 14,13 Phylogenetic analysis of sequences in the relatively well conserved 5' non-coding region (5'NCR) and in the core, NS-3 and NS-5 coding regions led to our classification of our own and other documented sequences into three major types-1, 1, and 3. Within the type 1 group, a subdivision is apparent on analysis of coding region se quences between the prototype sequences (HCV-1; type la) and those from Japanese patients (type lb). An .-J-.:!-'-equivalent subdivision is also apparent between type 2 sequences, corresponding to the K2a (type 2a) and K2b (type 2b) groups in the NS-5 region.®
In this study, we used restriction fragment length polymorphism (RFLP) analysis of viral sequences am plified in the 5'NCR to analyze the distribution of the three main types of HCV in Scottish blood donors. The extent to which sequence variability affects the recog nition of HCV antigens has been assessed by analysis of serologic reactivity between individual peptides used in commercially available confirmatory assays for anti-HCV with sera from individuals infected with different HCV types. Finally, the recall of HCV-infected individuals has permitted a comparison of risk factors for infection, age distribution, and extent of liver function abnormality associated with each type.
Materials and Methods

Samples
Approximately 147,000 volunteer blood donor samples col lected in Scotland and Northern Ireland were screened between September 1, 1991, and January 15, 1992, for antibody to HCV using a second-generation HCV enzyme immunoassay (EIA, Abbott GmBH, Wiesbaden-Deikenhein, Germany) or a second-generation HCV enzyme-linked immunosorbent assay (Ortho Diagnostic Systems, Raritan, NJ). Repeatably reactive samples were tested by second-generation recombinant immunoblot assay (RIBA, Chiron Corporation, Emeryville, CA) for antibody to 5-1-1, cl00-3, e33c, and c22-3 antigens and by iine immunoassay (LIA, Innogenetics, Antwerp, Bel gium) for antibody to NS-4, NS-5, and four different core oligopeptides. We carried out all antibody tests and interpreted (hem strictly in accordance with the manufacturers' instructions.
Donations that were positive (significant reactivity with two or more HCV antigens [1+ to 4+]) or indeterminate (reac tivity with one antigen only) in (he RIBA were tested for viral RNA by polymerase chain reaction (PCR). We tested donor samples for antibody to hepatitis B core antigen (anti-HBc) by radioimmunoassay (Abbott). Donors yielding RIBA-confirmed antibody-positive and/or PCR-positive donations were recalled for medical investigation and counseling in Glasgow and Edin burgh (Scotland), A single alanine aminotransferase (ALT) de termination was made in samples from the 90 recalled donors and from 100 randomly selected HCV-negative donors. The upper limit of (he normal range for the testing laboratory was 55 units per L. HCV sequences from hemophiliacs infected by factor VIII concentrates 16 were used for sequence comparisons. Flo. 1. Possible cleavage patterns for A) HaelU/Rsal (patterns a g) and B) ScrFl (patterns A-G) in the 5'NCR of published sequences of HCV (n = 19) and those obtained in this and our previous study'V (n = 59).
RNA PCR
supplementing the PCR buffer with 2 fiCi of P 5 S]-dAXPj (Amersham International, Amersham, UK) and reducing (he)' concentration of unlabeled nucleotide triphosphates to 8.25 (lA/f-(8,25 i^mol/L). 23 One |xL of the product was digested With 1; unit of ScrFl or 1 unit each offtwl and/faelll (all: Boehiinger, Mannheim UK, Lewes, UK) in 50 p-L of supplied restriction, buffer for 3 hours at 37°C.
The cleaved product was heated to 65°C for 5 minutes and! electrophoresed on a 12-percent polyacrylamide gel in lx ' 1 BE 1 ; (134 mM Tris, 68 mMboric acid, 2.5 mM BDTA, pH S.0) al^ 50 V for 18 hours or 160 V for 6 hours. After fixation in t\vqj' changes of 5-percent acetic acid and 5-percent methanol (3flV min each), the gel was dried and exposed to x-ray film for 3^"V days prior to development. We sized DNA fragments by confj parison with migration distances of standard-size DNA markcrs| (pBR322/BaeIII digest; Boehringer).
'f s ^tl
Results
Sequence variation in the 5'NCR
We compared 78 HCV sequences in the 5'NCR by standardsphylogenetic methods 15 and assigned (hem to HCV types 1,2,, and 3 (data not shown). A total of seven distinct cleavage patterns were predicted for the restriction endonucleases Hae\ 11 and/iml in combination (Fig. 1A) . All of the type 1 sequence?! obtained in this and our previous study, 16 as well as all pub-^ lisliul l\pt 1 sequences, produced restriction patterns a and b; !JP" 2 cqjences produced patterns c, d, and e, and all type 3 'ujii. nus produced patterns f and g ( Fig. 2A) Fig. 2A) . Types 1 and 3 are the predominant variants in Scot land (Table 1) ; 50 percent of donors were infected with type 1 and 40 percent with type 3, while type 2 accounted for the remaining 10 percent.
Serologic reactivity
A total of 45 of the 50 samples from subjects infected with HCV type 1 were positive in the first-generation anti-clOO EIA (Abbott) and showed broad reactivity with all four antigens in the RIBA and with the NS-4, NS-5, and core peptides in the LIA (Table 1 ; Fig, 3 ). By contrast, fewer of those infected with HCV types 2 and 3 (16/50) were anti-clOO positive, and samples showed weak or absent reactivity with the NS-4-derived antigens in the RIBA and LIA. Type 3 sera also showed weaker reactivity with c33c in the RIBA. Sera from type 3 samples were, however, equally reactive to the NS-5 peptides in the LIA and to each of the four core peptides, Almost all sera from infected individuals (98/100) reacted with the c22-3 antigen with a score of 4 +.
Sera from eight subjects found by RFLP to be infected with type 1 failed to react with some or all of nonstructural antigens. One possible explanation is that these individuals were infected with variants that had type 1 RFLP pattern in the 5'NCR but were divergent in sequence elsewhere in the genome. To in vestigate this, we amplified samples and sequenced them in the NS-3 (coding) region. Of the six samples that could suc cessfully be amplified with the NS-3 primers, five corre sponded closely to those of type la variants, while the last was more similar to type lb (data not shown).
Clinical correlations with HCV type
Anti-HBc was detected in 19 percent of samples from HCVinfected subjects (100 PCR-positive subjects; 13 samples from individuals who were anti-HCV positive but PCR negative; Table 1 ). We found similar frequencies among subjects in fected with different HCV types.
A total of 90 HCV-infected blood donors (38 infected with HCV type 1,10 with type 2,29 with type 3, and 13 who were confirmed antibody positive but were PCR negative and there fore were not typed) attended a donor follow-up clinic. As the ages of the donors were not distributed normally, they were compared by the nonparamefric Wilcoxon rank-sum test. This showed a significant difference between those infected with HCV types 1 and 3 (combined mean age, 30, 8) and those infected with HCV type 2 (mean age, 37.9; p<0.05; Table 2 ; Fig. 4A ). No significant difference was observed in the age distributions of those infected with type 1 or type 3 or those who were PCR negative (Fig. 4A) .
ALT values from each of the four categories of HCV-in fected individuals and a control group of 100 HCV antibodynegative donors are' shown in Fig. 4B . The Wilcoxon ranksum test was used to compare the distribution of values, and the x 2 test w as used for contingency analysis of numbers of samples over the upper limit of the normal range (55 units/L; Table 2 ). Both statistical methods indicated significant differ ences in ALT values in PCR-positive donors (i.e., types 1-3) and PCR-negative and HCV-uninfected donors (all p values <0.02). We observed no difference between the PCR-negative group and the controls. In both statistical tests, ALT levels were significantly higher (p<0.05, <0.025) in donors infected with HCV type 3 than in those infected with other types (type 3, 24/29 had abnormal ALT; type 1, 21/38; type 2; 6/13; Fig.  4B and 8 for HCV types 1, 2, and 3 and PCR negatives, respec tively). Among these samples, 11 were also negative on anticlOO testing (2, 3, 4, and 2 for HCV types 1, 2, and 3, and PCR negatives, respectively).
Discussion
Distribution of HCV types
The data presented in this article confirm our previous conclusion 14 that all three major types of HCV are pres ent in the British blood donor population. In Japan, type Approximately one-third of HCV-infected donors were negative for anti-HBc and had ALT values in the normal range, which is consistent with previous studies. 33 
Course of disease associated with different HCV types
All of the recalled donors were asymptomatic, al though approximately 60 percent had ALT values above the upper limit of the normal range. A significant finding was a clear difference in the distribution of ALT values in those who were PCR positive and those who were PCR negative (p<0.0001). Indeed, the ALT values of the latter group were comparable to those of the HCVnegative control donors.
It has been suggested that HCV type 2 may cause more severe disease and be less susceptible to interferon therapy than type I. 28 In our study, the distribution of ALT values of type 2-infected donors was similar to that of type 1-infected donors. However, their age distribu tion was not typical of blood donors and tended to be higher than that of donors infected with type 1 and type 3 variants, which suggests that infection had occurred longer ago and had had more time to resolve.
In contrast, donors infected with HCV types 1 and 3 were of similar age and had a similar incidence of past hepatitis B virus infection and reported risk factors for infection (in both cases, approximately 50% admitted past intravenous drug abuse). There was no association between HCV type and the geographical region within which the donor lived in Scotland or Northern Ireland, nor was there any association with specific areas, such as public housing, within a city. All but three of the donors were born in Scotland or Northern Ireland, and the majority are likely to have acquired infection from there. Thus, it is unlikely that simple epidemiologic dif ferences can account for the marked difference in the distribution of ALT values in the two groups (type 3: 83% abnormal ALT, compared with type 1: 55% ab normal; p<0.05). These differences raise the possibility that infection with type 3 is associated with greater liver damage and possibly a more severe course of disease than infection with type 1 and indicate a potential clinical role for HCV typing. However, despite the epidemio logic investigations, it remains possible that the higher ALT values in type 3-infected donors are the result of more recent infection and are perhaps associated with the infection of current drug abusers and their contacts in certain areas of Scotland. In addition, the higher ALT values do not necessarily reflect greater long-term dam age to the liver or the likelihood of complications such as cirrhosis and hepatocellular carcinoma. The full sig nificance of the differences in ALT values can therefore be determined only by further observation of the donors, ® to study the course of infection in more detail and to I carry out liver biopsies to investigate directly the extent j of liver disease. 
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